Document is current

Any future updates will be listed below

Correction to: Effect of Renal Impairment on Pharmacokinetics and Safety of Ensitrelvir, a SARS‑CoV‑2 3CL Protease Inhibitor

Crossref DOI link: https://doi.org/10.1007/s40121-024-01030-0

Published Online: 2024-08-13

Published Print: 2024-09

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark